[{"orgOrder":0,"company":"National Eye Institute","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"I27-Breg","moa":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"National Eye Institute","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"National Eye Institute \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"National Eye Institute \/ Not Applicable"},{"orgOrder":0,"company":"National Eye Institute","sponsor":"Trethera","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Funding","leadProduct":"TRE-515","moa":"dCK","graph1":"Oncology","graph2":"Phase I","graph3":"National Eye Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"National Eye Institute \/ National Eye Institute","highestDevelopmentStatusID":"6","companyTruncated":"National Eye Institute \/ National Eye Institute"},{"orgOrder":0,"company":"National Eye Institute","sponsor":"Praetego","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Funding","leadProduct":"PTG-630","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"National Eye Institute","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"National Eye Institute \/ National Eye Institute","highestDevelopmentStatusID":"4","companyTruncated":"National Eye Institute \/ National Eye Institute"},{"orgOrder":0,"company":"National Eye Institute","sponsor":"iVeena","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2023","type":"Funding","leadProduct":"IVMED-85","moa":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"National Eye Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"National Eye Institute \/ National Eye Institute","highestDevelopmentStatusID":"7","companyTruncated":"National Eye Institute \/ National Eye Institute"},{"orgOrder":0,"company":"National Eye Institute","sponsor":"RevOpsis Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Large molecule","year":"2024","type":"Funding","leadProduct":"RO-104","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"National Eye Institute","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"National Eye Institute \/ National Eye Institute","highestDevelopmentStatusID":"14","companyTruncated":"National Eye Institute \/ National Eye Institute"}]